New dosing regimen for asparaginase erwinia chrysanthemi (recombinant) is approved by FDA

Share This Post

Dec 2022: A new Monday-Wednesday-Friday dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn has been approved by the Food and Drug Administration (Rylaze, Jazz Pharmaceuticals). Patients should receive 25 mg/m2 intramuscularly on Monday and Wednesday in the morning and 50 mg/m2 intramuscularly on Friday in the afternoon under the modified protocol. Additionally, it is permitted to be injected intramuscularly at a dose of 25 mg/m2 every 48 hours.

In June 2021, the FDA authorised Rylaze as a part of a multi-agent chemotherapy regimen for adult and paediatric patients with acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) who have developed an allergy to asparaginase produced from E. coli.

In Study JZP458-201 (NCT04145531), an open-label multicenter experiment in which Rylaze was delivered at various dosages and methods, the pharmacokinetics of Rylaze were assessed in 225 patients. The results were used to create a model to forecast blood asparaginase activity at various timepoints.

Based on a simulation in a fictitious population, the achievement and maintenance of nadir serum asparaginase activity (NSAA) above the level of 0.1 U/mL was used to determine efficacy. Following the 25 mg/m2 dose of Rylaze on Wednesday morning and the 50 mg/m2 dose on Friday afternoon, according to simulation results, the proportion of patients maintaining NSAA 0.1 U/mL would be 91.6% (95% CI: 90.4%, 92.8%) and 91.4% (95% CI: 90.1%, 92.6%), respectively.

Neutropenia, anaemia, or thrombocytopenia were observed in all patients given Rylaze at the indicated dosages as part of multi-agent chemotherapy. Atypical liver tests, nausea, musculoskeletal pain, infections, fatigue, headaches, febrile neutropenia, pyrexia, haemorrhage, stomatitis, abdominal pain, decreased appetite, drug hypersensitivity, hyperglycemia, diarrhoea, pancreatitis, and hypokalemia were the most frequent nonhematological adverse reactions (incidence > 20%) in patients.

View full prescribing information for Rylaze.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

How Targeted Therapy is Revolutionizing Advanced Cancer Treatment

How Targeted Therapy is Revolutionizing Advanced Cancer Treatment?

In the field of oncology, the emergence of targeted therapy has revolutionized the treatment landscape for advanced cancers. Unlike conventional chemotherapy, which broadly targets rapidly dividing cells, targeted therapy aims to selectively attack cancer cells while minimizing damage to normal cells. This precision approach is made possible by identifying specific molecular alterations or biomarkers that are unique to cancer cells. By understanding the molecular profiles of tumors, oncologists can tailor treatment regimens that are more effective and less toxic. In this article, we delve into the principles, applications, and advancements of targeted therapy in advanced cancer.

Utilizing Immunotherapy to Treat Late-Stage Cancers

Utilizing Immunotherapy to Treat Late-Stage Cancers

  Introduction Immunotherapy has become a groundbreaking method in cancer treatment, especially for advanced-stage cancer treatments that have demonstrated minimal effectiveness with standard medicines. This

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy